Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Survival Analysis01:21

Cancer Survival Analysis

470
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
470

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The gut microbiome in obesity: new horizons in personalized medicine].

Terapevticheskii arkhiv·2026
Same author

[Stage I cholelithiasis. Approaches to diagnosis and treatment. Results of the Machaon study].

Terapevticheskii arkhiv·2025
Same author

Editorial on the article «Natriuretic Peptide Concentrations and Echocardiography Findings in Patients with Micro-atrial Fibrillation».

Kardiologiia·2024
Same author

[The role of the phenosanic acid in the combined treatment of patients with epilepsy].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2023
Same author

Electrocardiogram QRS Complex Duration as a Predictor of Hospital Prognosis in Patients With COVID-19.

Kardiologiia·2023
Same author

[The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities].

Terapevticheskii arkhiv·2022

Related Experiment Video

Updated: Sep 23, 2025

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.5K

[Пятилетнее исследование влияния кардиомониторинга на общую выживаемость больных хроническим лимфолейкозом,

E I Emelina1, G E Gendlin1, I G Nikitin1

  • 1Pirogov Russian National Research Medical University, Moscow.

Kardiologiia
|May 15, 2022
PubMed
Summary

Active cardiac monitoring significantly improves overall survival for chronic lymphoid leukemia (CLL) patients on ibrutinib therapy. This approach helps manage cardiovascular side effects like atrial fibrillation and hypertension, leading to better long-term outcomes.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.5K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.9K

Related Experiment Videos

Last Updated: Sep 23, 2025

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.5K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.5K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

14.9K

Area of Science:

  • Oncology
  • Cardiology
  • Hematology

Background:

  • Cardiovascular comorbidities and treatment-induced cardiotoxicity significantly impact survival in cancer patients.
  • The need for regular cardiological monitoring in cancer patients receiving targeted therapies remains a critical, unresolved issue.
  • Ibrutinib, a targeted therapy for chronic lymphoid leukemia (CLL), has known side effects including atrial fibrillation (AF) and arterial hypertension (AH).

Purpose of the Study:

  • To evaluate the impact of active cardiac monitoring on the overall survival of CLL patients treated with ibrutinib.
  • To assess the effectiveness of managing cardiovascular side effects, such as AF and AH, in CLL patients undergoing ibrutinib therapy.

Main Methods:

  • A prospective 5-year study involving 217 CLL patients on ibrutinib therapy.
  • Patients were divided into an active cardiac monitoring group (n=89) with weekly remote monitoring and a standard follow-up group (n=128).
  • Evaluations included electrocardiography, echocardiography, comorbidity assessment (Charlson's index), and frailty assessment (Geriatric 8, Groningen Frailty Index).

Main Results:

  • The active cardiac monitoring group showed significantly higher overall 5-year survival rates compared to the standard follow-up group (p<0.0001).
  • Patients in the active monitoring group had significantly better achievement of blood pressure goals (90.9% vs. 39.9%, p<0.0001) and higher rates of cardiac interventions (12 vs. 0, p=0.0004).
  • Active monitoring was associated with improved survival across various subgroups, including men, women, older patients, and those with specific genetic abnormalities.

Conclusions:

  • Continuous cardiologist involvement, particularly through active cardiac monitoring with remote control, significantly enhances overall survival in CLL patients on ibrutinib.
  • Achieving stable blood pressure goals and proactive management of AF and other cardiovascular complications are key factors contributing to improved survival.
  • Active cardiac monitoring is a crucial strategy for improving long-term outcomes in onco-hematological patients receiving targeted therapies like ibrutinib.